Cyra Patel

Cyra Patel

Auto-generated profile, based on publicly available information

Cyra Patel

University of Sydney Sydney New South Wales Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2023 in Global Health: Science and Practice
Verified
Journal Article
Open access
PDF file
CPCyra Patel
Cyra Patel
NRNicole Rendell
Nicole Rendell
GSGinny M. Sargent
Ginny M. Sargent
AAAkeem Ali
Akeem Ali
CMChristopher Morgan
Christopher Morgan
MSMeru Sheel
Meru Sheel
Background: Vaccination coverage is widely used to assess immunization performance but, on its own, provides insufficient information to drive improvements. Assessing the performance of underlying components of immunization systems is less clear, with several monitoring and evaluation (M&E) resources available for use in different operational settings and for different purposes. We studied these resources to understand how immunization system performance is measured. Methods: We reviewed peer-reviewed and gray literature published since 2000 to identify M&E resources that include national-level indicators measuring the performance of immunization systems or their components (governance, financing, regulation, information systems, vaccine logistics, workforce, service delivery, and demand generation). We summarize indicators by the system components or outcomes measured and describe findings narratively. Results: We identified 20 resources to monitor immunization program objectives and guide national strategic decision-making, encompassing 631 distinct indicators. Indicators for immunization program outcomes comprised the majority (124/631 [19.7%]), largely vaccination coverage (110/124 [88.7%]). Almost all resources (19/20 [95%]) included indicators for vaccine logistics (83/631 [13.2%]), and those for regulation (19/631 [3.0%]) and demand generation (28/631 [4.4%]) were least common. There was heterogeneity in how information systems (92/563 [14.6%]) and workforce (47/631 [7.4%]) were assessed across resources. Indicators for vaccination coverage in adults, data use in decision-making, equity and diversity, effectiveness of safety surveillance, and availability of a public health workforce were notably lacking. Conclusions: Between the resources identified in this review, we identified considerable variability and gaps in indicators assessing the performance of some immunization system components. Given the multitude of indicators, policymakers may be better served by tailoring evaluation resources to their specific context to gain useful insight into health system performance and improve data use in decision-making for immunization programs. Key Findings We reviewed monitoring and evaluation (M&E) resources to understand how national immunization system performance has been measured, identifying 631 distinct M&E indicators that reflect the increasing complexity of immunization programs and the changing policies, priorities, and reporting requirements of immunization actors at the global level. This study highlights the substantial workload associated with the large burden of data collection and routine reporting for immunization alone, especially in resource-constrained settings. Despite the large number of indicators identified, gaps remain in measuring key areas of immunization, such as adult immunization, data use in decision-making, and equity and diversity, where efforts are needed to develop and validate indicators. Key Implications This review can inform country-specific approaches to measuring system performance moving forward, particularly as countries seek to strengthen immunization programs by leveraging investments made during the COVID-19 response. Public health practitioners can streamline how immunization is measured by selecting a core set of indicators that align with the priorities, values, and challenges within their specific setting.

18 December 2024 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
XWXia Wang
Xia Wang
CPCyra Patel
Cyra Patel
MGMichelle Giles
Michelle Giles
PBPenny L. Burns
Penny L. Burns
KMKristine Macartney
Kristine Macartney
PWPhoebe C Williams
Phoebe C Williams
Despite widespread adoption of “high-dose” glucocorticoid definitions across international immunisation guidelines (ie, prednisone-equivalent dosing >20 mg/day, or >2 mg/kg/day in children), the rationale remains unclear. Literature searches were performed through academic databases for this narrative review to identify relevant evidence regarding glucocorticoid dosing on vaccine responses and safety. In people receiving prednisone 20 mg/day), antibody titres and seropositivity are reduced, whereas the impact of low- to medium-dose glucocorticoids (7 to 20 mg/day) on vaccine efficacy remains inconclusive. Due to inconsistent paediatric dosing regimens, data is insufficient to support a unified “high-dose” glucocorticoid threshold. Non-live vaccines are well tolerated in patients receiving glucocorticoids with rheumatic/inflammatory disorders, but enhanced reactogenicity after live vaccination may occur in those with severe immunodeficiencies. Clinicians should consider individual risk-benefit profiles, rather than following strict dosing thresholds, when curating immunisation programs for patients prescribed glucocorticoids.

25 August 2025 in Vaccine
Verified
Journal Article
Open access
CPCyra Patel
Cyra Patel
XWXia Wang
Xia Wang
MGMichelle Giles
Michelle Giles
PBPenelope Burns
Penelope Burns
TNTran Nguyen
Tran Nguyen
PWPhoebe C.M. Williams
Phoebe C.M. Williams
Immunocompromised individuals are at high risk of vaccine-preventable diseases, but typically have impaired immune responses to vaccination and require altered vaccination schedules. Serological testing can inform vaccination decisions in this vulnerable population, but is frequently ordered inappropriately. Furthermore, misinterpretion of serological results can misguide clinical decisions. We reviewed existing recommendations and supporting literature to define key criteria for appropriate serological testing in immunocompromised persons. We identified three key criteria: 1) there must be an established immune correlate of protection; 2) there must be a reliable, validated commercial serology test; and 3) test results must inform clinical decisions around vaccination or post-exposure prophylaxis. Serology results can most accurately guide clinical decision-making for hepatitis B, measles, rabies, rubella and yellow fever. In this article, we provide a synthesis of this published evidence to guide clinicians and vaccine providers on the appropriate utilisation of serological testing.

25 July 2024 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
CPCyra Patel
Cyra Patel
GSGinny M. Sargent
Ginny M. Sargent
ATAdeline Tinessia
Adeline Tinessia
HMHelen J Mayfield
Helen J Mayfield
DCDan Chateau
Dan Chateau
Meru SheelMeru Sheel
Meru Sheel
Increasing countries’ access to data can improve immunisation coverage through evidence-based decision-making. However, data collection and reporting is resource-intensive, so needs to be pragmatic, especially in low-and-middle-income countries. We aimed to identify which indicators are most important for measuring, and improving, national immunisation performance in Pacific Island Countries (PICs). We conducted an expert elicitation study, asking 13 experts involved in delivering immunisation programs, decision-makers, health information specialists, and global development partners across PICs to rate 41 indicators based on their knowledge of the feasibility and relevance of each indicator. We also asked experts their preferences for indicators to be retained or removed from a list of indicators for PICs. Experts participated in two rating rounds, with a discussion on the reasons for ratings before the second round. We calculated mean scores for feasibility and relevance, and ranked indicators based on experts’ preferences and mean scores. We used framework analysis to identify reasons for selecting indicators. Experts agreed that certain indicators were essential to measure (e.g. data use in program planning and measles vaccination coverage), but preferences varied for most indicators. Preferences to include indicators in a set of indicators for PICs moderately correlated with scores for relevance (r = 0.68) and feasibility (r = 0.56). In discussions, experts highlighted usefulness for decision-making and ease of data collection, reporting and interpretation as the main reasons driving indicator selection. Country-specific factors such as health system factors, roles and influence of various immunisation actors, and macro-level factors (namely population size, distribution and mobility) affected relevance and feasibility, leading us to conclude that a single set of indicators for all PICs is inappropriate. Rather than having a strict set of indicators that all countries must measure and report against, performance indicators should be flexible, country-specific, and selected in consultation with immunisation actors who collect and use the data.

17 September 2025 in Discover Public Health
Verified
Journal Article
Open access
PDF file
CPCyra Patel
Cyra Patel
OCOlivia Y. Cheung
Olivia Y. Cheung
RTRachel Takoar
Rachel Takoar
CGChris Gauthier-Coles
Chris Gauthier-Coles
GSGinny M. Sargent
Ginny M. Sargent
Meru SheelMeru Sheel
Meru Sheel
Electronic immunisation registers (EIRs) can strengthen immunisation programs by increasing access to rich data for policy-making. In Vanuatu, an EIR was i

19 June 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
Meru SheelMeru Sheel
Meru Sheel
CPCyra Patel
Cyra Patel
GSGemma Saravanos
Gemma Saravanos
MLMichelle Lynch
Michelle Lynch
ATAdeline Tinessia
Adeline Tinessia
M. Carolina DanovaroM. Carolina Danovaro
M. Carolina Danovaro
Background: Electronic immunization registers (EIRs) can strengthen immunization systems and, if used effectively, can lead to greater efficiency and improvements in vaccination coverage. Several low- and middle-income countries introduced EIRs for COVID-19 vaccination and are now integrating them for routine immunization. Objective: This study aims to describe the protocol used to evaluate the implementation of an EIR in the Lao People’s Democratic Republic in 2022. In addition, it seeks to identify opportunities to improve implementation, scale-up, and sustainability in the country. Methods: To evaluate the implementation of the EIR in the Lao People’s Democratic Republic, we will (1) map the EIR workflow process, (2) examine EIR user and stakeholder perspectives, and (3) assess the EIR data quality. Data will be collected and analyzed through a mixed methods approach. This evaluation will involve a document review, observation of workflows in health facilities, health facility user surveys, key informant interviews with decision makers, and an assessment of immunization data quality. This protocol details the methods for each of these components. The evidence generated will be triangulated to identify the strengths and weaknesses of the early implementation phase of the EIR, facilitators of and barriers to the implementation, and whether the introduction of the EIR has improved immunization data processes and quality compared with paper-based processes. Results: Data collection took place between April 2024 and August 2024. Data analysis is currently ongoing, with results expected to be shared with study stakeholders in October 2024. Conclusions: This early evaluation will contribute to developing a road map for the nationwide strengthening and sustainability of the EIR based on challenges and lessons learned, potentially streamlining further implementation efforts and enabling more effective use of the EIR. This paper presents a methodology for evaluating EIR implementation that can be replicated in other low- and middle-income countries implementing EIRs. International Registered Report Identifier (IRRID): DERR1-10.2196/65663